"If Mr. Johnson really believed in the U.K. as a science superpower, he would not be in favor of Brexit. The prime minister's announcement may be a positive step, but the brute fact remains that Brexit is absolutely dreadful news for U.K. science. We know that EU scientists have already left, talented young people have decided not to come here, and U.K. scientists have been excluded from EU projects because of Brexit,"
John Krebs, professor at Oxford University, commenting on government plans to preserve the status of U.K. research by setting up a new fast track visa system to attract top scientists post-Brexit
"This emerging species has existed for thousands of years, but this is the first time anyone has studied C. difficile genomes in this way to identify it. Our large-scale genetic analysis allowed us to discover that C. difficile is currently forming a new species, with [clade A] specialized to spread in hospital environments."
Nitin Kumar, of the Wellcome Sanger Institute in Cambridge, U.K., an author of a paper published in the Aug. 12, 2019, online edition of Nature Genetics describing research that found changes in genes that enable the emerging species, C. difficile clade A, to metabolize sucrose and fructose, and showed the bacterium better colonized mice when their diet was enriched with sugar
"Investors with a good understanding of the bio sector have increased over the past 10 years. I believe there is a high possibility of developing blockbuster new drugs in Korea because of high-quality R&D, concentration on first-class drugs, and the rapid increase in funding. There will be a critical tipping point in two to three years for Korean biopharmaceutical companies, and investment will impact their success."
James Jungkue Lee, CEO of Bridge Biotherapeutics Inc.